SUWANEE, GA--(Marketwired - Jun 13, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) today announced that Uptick network will release an in-depth interview with CEO and Chairman, Kevin A. Richardson II. The interview details a discussion about the Company's pending FDA approval process, their rapid growth internationally, and the recently announced AI deal with eKARE, which pushes them to the forefront of wound management. The interview will be released on the following sites:

• Uptick Newswire's heavily trafficked website with over 20,000 daily visitors.
• Audio Publication to the Audio Boom Channel, Audio Boom has 148,000+ unique visitors
• Audio will be featured on the front page of Investors Hangout, Investors Hangout has over 30,000 Investors visiting the site daily
• Audio Published on iHeartRadio Channel, iHeartRadio's webpage alone has over 361,000 daily visitors
• Placement on iTunes Website, iTunes has over 62,000,000 daily unique visitors trafficking the site. Uptick has its own iTunes Webpage that will feature the audio interview 

Along with Audio Boom, Investors Hangout, iHeartRadio and iTunes, the Audio will be distributed and featured on: Stitcher, aCast.com, Spreaker, Player.fm, Google Play, FeedBurner.com, and Podcast Directory, Uptick's YouTube Channel.

Mr. Richardson commented, "Everett and his team at Uptick have developed a great niche to get the investment story out for many interesting companies. We are excited to be part of this unique distribution opportunity." 

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB: SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's de novo petition review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit www.sanuwave.com.